Observational studyBritish journal of cancer2021
Clinical impact of PET/MRI in oligometastatic colorectal cancer.
Observational study in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06265272 (Technical Development and Clinical Validation of a Comprehensive One-stop Shop Assessment of the Cirrhotic Liver With [68Ga]Ga-PSMA-11 PET/MRI), which is not on this map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Technical Development and Clinical Validation of a Comprehensive One-stop Shop Assessment of the Cirrhotic Liver With [68Ga]Ga-PSMA-11 PET/MRI
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The Role of Radiologists in Multidisciplinary Tumor Boards for Colorectal Cancer with Liver Metastases: a Systematic Review.Current oncology reports · 2025Pooled it
- FDG-PET/MRI in colorectal cancer care: an updated systematic review.Abdominal radiology (New York) · 2025Pooled it
- Diagnostic performance of [European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Peritoneal Metastases Challenge the Radiologist as Much as the Surgeon: Can Magnetic Resonance Imaging be a Beacon of Light for Both?Annals of surgical oncology · 2026Article
- Standard of practice imaging vs. PET/MR: a comparative prospective study in rectal cancer staging.International journal of colorectal disease · 2025Article
- Young-onset metastatic colorectal cancer: an opportunity and a vision for progress in cancer.Medical oncology (Northwood, London, England) · 2025Review
- PET/MRI: pictorial review of hepatobiliary and pancreatic applications.Abdominal radiology (New York) · 2025Review
- Influence of Covariates onDiagnostics (Basel, Switzerland) · 2024Article
- PET/MRI in colorectal and anal cancers: an update.Abdominal radiology (New York) · 2023Review
- Nuclear Medicine and Cancer Theragnostics: Basic Concepts.Diagnostics (Basel, Switzerland) · 2023Review
- FAPI PET/CT in Diagnostic and Treatment Management of Colorectal Cancer: Review of Current Research Status.Journal of clinical medicine · 2023Review
- Role of one-step nucleic acid amplification in colorectal cancer lymph node metastases detection.World journal of gastroenterology · 2022Review
- Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease.Molecular imaging and biology · 2022Article
- State of the art of PET/MRI for rectal cancer: the added value to conventional imaging.Radiologia brasileiraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOligometastatic colorectal cancer (CRC) is potentially curable and demands individualised strategies.
methodsThis single-centre retrospective study investigated if positron emission tomography (PET)/magnetic resonance imaging (MR) had a clinical impact on oligometastatic CRC relative to the standard of care imaging (SCI). Adult patients with oligometastatic CRC on SCI who also underwent PET/MR between 3/2016 and 3/2019 were included. The exclusion criterion was lack of confirmatory standard of reference, either surgical pathology, intraoperative gross confirmation or imaging follow-up. SCI consisted of contrast-enhanced (CE) computed tomography (CT) of the chest/abdomen/pelvis, abdominal/pelvic CE-MR, and/or CE whole-body PET/CT with diagnostic quality (i.e. standard radiation dose) CT. Follow-up was evaluated until 3/2020.
resultsThirty-one patients constituted the cohort, 16 (52%) male, median patient age was 53 years (interquartile range: 49-65 years). PET/MR and SCI results were divergent in 19% (95% CI 9-37%) of the cases, with PET/MR leading to management changes in all of them. The diagnostic accuracy of PET/MR was 90 ± 5%, versus 71 ± 8% for SCI. In a pairwise analysis, PET/MR outperformed SCI when compared to the reference standard (p = 0.0412).
conclusionsThese findings suggest the potential usefulness of PET/MR in the management of oligometastatic CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.